Posted by Michael Wonder on 22 Apr 2026
Biocon receives Health Canada approval of Bosaya (denosumab) and Vevzuo (denosumab), biosimilars to Prolia and Xgeva
21 April 2026 - Biocon is pleased to announce that Health Canada has granted a Notice of Compliance for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar to Xgeva, on 3 April 2026.
Both biosimilars were approved in the most common presentations: Bosaya, as a 60 mg/mL injection for subcutaneous use in a pre-filled syringe; and Vevzuo, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.
